{
    "AML": {
        "Induction Therapy": {
            "goal": "To achieve complete remission by eradicating visible leukemic blasts and restoring normal hematopoiesis.",
            "protocols": [
                {
                    "protocolName": "7+3 (Cytarabine + Daunorubicin/Idarubicin)",
                    "drugs": [
                        {
                            "phase": "Pre-Chemo",
                            "day": "Day 1",
                            "name": "Ondansetron",
                            "dose": "8 mg",
                            "route": "IV",
                            "duration": "15 min"
                        },
                        {
                            "phase": "Pre-Chemo",
                            "day": "Day 1",
                            "name": "Prednisolone eye drops",
                            "dose": "1 drop each eye",
                            "route": "Eye drops",
                            "duration": "2 hours before Cytarabine"
                        },
                        {
                            "phase": "Chemo",
                            "day": "Days 1–3",
                            "name": "Daunorubicin or Idarubicin",
                            "dose": "60 mg/m²/day over 5-15 min or 12 mg/m²/day over 10-15 min",
                            "route": "IV",
                            "duration": "3 days"
                        },
                        {
                            "phase": "Chemo",
                            "day": "Days 1–7",
                            "name": "Cytarabine (Ara-C)",
                            "dose": "100 mg/m²/day",
                            "route": "IV continuous infusion",
                            "duration": "24 hours"
                        },
                        {
                            "phase": "Post-Chemo",
                            "day": "Day 8",
                            "name": "Filgrastim",
                            "dose": "5 mcg/kg",
                            "route": "SC",
                            "duration": "Continue until ANC ≥ 1000 two consective days"
                        }
                    ],
                    "NursesInfo": [
                        "Indication: AML induction",
                        "Administer anthracycline (Daunorubicin/Idarubicin) only after completion of the previous day's Cytarabine infusion.",
                        "Use central venous line (PICC/CVC) for Idarubicin or Daunorubicin— avoid peripheral veins.",
                        "Side effects: \"Cytarabine syndrome\", \"Tumour lysis syndrome\", Nausea and Vomiting"
                    ],
                    "source": "Hospital Protocol"
                },
                {
                    "protocolName": "FLAG-IDA (Fludarabine + Cytarabine + G-CSF + Idarubicin)",
                    "drugs": [
                        {
                            "day": "Day 1 - until ANC recovery",
                            "name": "Filgrastim (G-CSF)",
                            "dose": "5 mcg/kg or 480 mcg / day",
                            "route": "Subcutaneus",
                            "duration": "Continue until ANC ≥ 1000 two consective days"
                        },
                        {
                            "day": "Days 2–4",
                            "name": "Idarubicin",
                            "dose": "10 mg/m²/day over 10-15 min",
                            "route": "IV",
                            "duration": ""
                        },
                        {
                            "day": "Days 2–6",
                            "name": "Fludarabine",
                            "dose": "30 mg/m²/day over 30 min",
                            "route": "IV infusion",
                            "duration": ""
                        },
                        {
                            "day": "Days 2–6",
                            "name": "Cytarabine",
                            "dose": "2 g/m²/day over 4 hours",
                            "route": "IV infusion",
                            "duration": "4 hours after Fluderabine"
                        }
                    ],
                    "NursesInfo": [
                        "Indication: High-risk AML: adverse cytogenetics, TP53 mutation, secondary AML (sAML/t-AML), FLT3-ITD high ratio, hyperleukocytosis, transplant-intent patients",
                        "Side effects: \"Cytarabine syndrome\", \"Tumour lysis syndrome\", Cytarabine induced neurotoxicity, Nausea and Vomiting"
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Consolidation Therapy": {
            "goal": "To eliminate residual leukemic cells and consolidate remission achieved during induction.",
            "protocols": [
                {
                    "protocolName": "Cytarabine (age under 60 years)",
                    "drugs": [
                        {
                            "day": "Days 1–3",
                            "name": "Cytarabine (Ara-C)",
                            "dose": "1.5 g/m² over 3 hours every 12 hours",
                            "route": "IV infusion",
                            "duration": "28 days or after BM recovey. 2 to 4 cycles"
                        }
                    ],
                    "NursesInfo": [
                        "Indication: AML in remission in patients who are under 60 years of age.",
                        "Side effects: \"Cytarabine syndrome\", \"Tumour lysis syndrome\", Cytarabine induced neurotoxicity, Nausea and Vomiting"
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Cytarabine (age 60 years and over)",
                    "drugs": [
                        {
                            "day": "Days 1–3",
                            "name": "Cytarabine (Ara-C)",
                            "dose": "1 g/m² over 3 hours every 12 hours",
                            "route": "IV infusion",
                            "duration": "28 days or after BM recovey. 2 to 4 cycles"
                        }
                    ],
                    "NursesInfo": [
                        "Indication: AML in remission in patients who are aged 60 years aand over.",
                        "Side effects: \"Cytarabine syndrome\", \"Tumour lysis syndrome\", Cytarabine induced neurotoxicity, Nausea and Vomiting"
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "HiDAC-High dose Cytarabine (Ara-c)",
                    "drugs": [
                        {
                            "day": "Days 1, 3, 5",
                            "name": "Cytarabine (Ara-C)",
                            "dose": "3 g/m² over 3 hours every 12 hours",
                            "route": "IV infusion",
                            "duration": "28 days or after BM recovey. 3 cycles"
                        }
                    ],
                    "NursesInfo": [
                        "Indication: AML in remission in patients who are under 60 years of age.",
                        "Side effects: \"Cytarabine syndrome\", \"Tumour lysis syndrome\", Cytarabine induced neurotoxicity, Nausea and Vomiting"
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Maintenance Therapy": {
            "goal": "To maintain remission, prolong survival, and delay relapse in patients not undergoing transplant.",
            "protocols": [
                {
                    "protocolName": "Azacitidine Oral",
                    "drugs": [
                        {
                            "day": "Days 1–14 of each 28-days",
                            "name": "Azacitidine ",
                            "dose": "300 mg Daily for 14 days",
                            "route": "Oral",
                            "duration": "Continous until disease progression orunacceptable toxicity."
                        }
                    ],
                    "NursesInfo": [
                        "Premediication Granisetron / Ondansetron oral",
                        "Nausea, vomiting, and diarrhea are common.",
                        "The oral formulation of azacitidine is not interchangeable with injectable formulation"
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Azacitidine SC",
                    "drugs": [
                        {
                            "day": "Days 1–7 of each 28-days",
                            "name": "Azacitidine",
                            "dose": "75 mg/m²",
                            "route": "SC",
                            "duration": "6 cycles minimum, then continue until disease progression."
                        }
                    ],
                    "NursesInfo": [
                        "Premediication Ondansetron oral",
                        "Nausea, vomiting, and diarrhea are common.",
                        "Can also be administered as IV"
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Low-Dose Cytarabine (Ara-C)",
                    "drugs": [
                        {
                            "day": "Day 1 to 10 for 4 - 6 weeks",
                            "name": "Cytarabine (Ara-C)",
                            "dose": "20 mg TWICE a day",
                            "route": "Subcutaneus",
                            "duration": "Continuous until disease progression or unacceptable toxicity."
                        }
                    ],
                    "NursesInfo": [
                        "Indication: AML in patients deemed unfit for intensive chemotherapy",
                        "Treatment with cytarabine may cause a \"cytarabine syndrome\" and \"Tumour lysis syndrome\".",
                        ""
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Salvage Therapy": {
            "goal": "To reinduce remission in refractory AML or aggressive relapse and provide a bridge to transplant when possible.",
            "protocols": [
                {
                    "protocolName": "FLAG-IDA (Fludarabine + Cytarabine + G-CSF + Idarubicin)",
                    "drugs": [
                        {
                            "day": "Day 1 - until ANC recovery",
                            "name": "Filgrastim (G-CSF)",
                            "dose": "5 mcg/kg or 480 mcg / day",
                            "route": "Subcutaneus",
                            "duration": "Continue until ANC ≥ 1000 two consective days"
                        },
                        {
                            "day": "Days 2–4",
                            "name": "Idarubicin",
                            "dose": "10 mg/m²/day over 10-15 min",
                            "route": "IV",
                            "duration": ""
                        },
                        {
                            "day": "Days 2–6",
                            "name": "Fludarabine",
                            "dose": "30 mg/m²/day over 30 min",
                            "route": "IV infusion",
                            "duration": ""
                        },
                        {
                            "day": "Days 2–6",
                            "name": "Cytarabine",
                            "dose": "2 g/m²/day over 4 hours",
                            "route": "IV infusion",
                            "duration": "4 hours after Fluderabine"
                        }
                    ],
                    "NursesInfo": [
                        "Indication: High-risk AML: adverse cytogenetics, TP53 mutation, secondary AML (sAML/t-AML), FLT3-ITD high ratio, hyperleukocytosis, transplant-intent patients",
                        "Side effects: \"Cytarabine syndrome\", \"Tumour lysis syndrome\", Cytarabine induced neurotoxicity, Nausea and Vomiting"
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "MEC (Mitoxantrone + Etoposide + Cytarabine)",
                    "drugs": [
                        {
                            "day": "Days 1–6",
                            "name": "Mitoxantrone",
                            "dose": "6 mg/m²",
                            "route": "IV over 30 min",
                            "duration": ""
                        },
                        {
                            "day": "Days 1–6",
                            "name": "Etoposide",
                            "dose": "80 mg/m²",
                            "route": "IV over 1 hours",
                            "duration": ""
                        },
                        {
                            "day": "Days 1–5",
                            "name": "Cytarabine",
                            "dose": "1 g/m² TWICE daily",
                            "route": "IV over 3 hours",
                            "duration": "Cycle length 28 days"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor for cardiotoxicity and mucositis.",
                        "High TLS risk — hydration and allopurinol required.",
                        "Watch for severe pancytopenia; transfusion support expected."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "CLAG-M (Cladribine + Cytarabine + G-CSF + Mitoxantrone)",
                    "drugs": [
                        {
                            "day": "Days 1-until ANC recovey",
                            "name": "Filgrastim (G-CSF)",
                            "dose": "5 µg/kg/day",
                            "route": "SC",
                            "duration": "Start 24 h pre-chemo"
                        },
                        {
                            "day": "Days 2-4",
                            "name": "Mitoxantrone",
                            "dose": "10 mg/m²/day",
                            "route": "IV",
                            "duration": "15–30 min"
                        },
                        {
                            "day": "Days 2-6",
                            "name": "Cladribine",
                            "dose": "5 mg/m²/day",
                            "route": "IV",
                            "duration": "over 2 hours"
                        },
                        {
                            "day": "Days 2-6",
                            "name": "Cytarabine (Ara-C)",
                            "dose": "2 g/m²/day",
                            "route": "IV infusion",
                            "duration": "Start 2 hours after Cladrabine finishes, over 4 hours "
                        }
                    ],
                    "NursesInfo": [
                        "Highly myelosuppressive — anticipate prolonged neutropenia.",
                        "Monitor neurological status (high-dose cytarabine).",
                        "Ensure TLS prophylaxis and aggressive hydration."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        }
    },
    "ALL": {
        "Induction Therapy": {
            "goal": "To achieve complete remission with age- and subtype-appropriate regimens.",
            "protocols": [
                {
                    "protocolName": "Ph+ ALL – Ponatinib + Blinatumomab",
                    "drugs": [
                        {
                            "day": "Cycle 1–2",
                            "name": "Ponatinib",
                            "dose": "30 mg daily",
                            "route": "Oral",
                            "duration": "Continuous"
                        },
                        {
                            "day": "Cycle 1–2",
                            "name": "Blinatumomab",
                            "dose": "9 mcg/day → 28 mcg/day",
                            "route": "IV",
                            "duration": "28 days continuous infusion"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor for cytokine release and neurotoxicity; ensure dedicated IV line for Blinatumomab."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Ph– ALL (14–50 yrs) – R-BFM + Blinatumomab",
                    "drugs": [
                        {
                            "day": "1–33",
                            "name": "BFM protocol drugs",
                            "dose": "Per schedule",
                            "route": "Various",
                            "duration": "33 days"
                        },
                        {
                            "day": "Post induction",
                            "name": "Blinatumomab",
                            "dose": "As per MRD status",
                            "route": "IV",
                            "duration": "28 days"
                        }
                    ],
                    "NursesInfo": [
                        "Ensure adherence to schedule; monitor LFTs and blood counts."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Consolidation Therapy": {
            "goal": "To eliminate residual disease after induction. Uses HyperCVAD A & B alternate 8 cycles every 28 days",
            "protocols": [
                {
                    "protocolName": "HyperCVAD Cycle A",
                    "drugs": [
                        {
                            "day": "Day 1-3",
                            "name": "Cyclophosphamide",
                            "dose": "300 mg/m² every 12 hours × 6 doses",
                            "route": "IV",
                            "duration": "Over 3 hours"
                        },
                        {
                            "day": "Day 1–3",
                            "name": "Mesna",
                            "dose": "600 mg/m²/day (divided doses)",
                            "route": "IV/PO",
                            "duration": "Given with cyclophosphamide"
                        },
                        {
                            "day": "Day 1-4",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "4 Days"
                        },
                        {
                            "day": "Day 4",
                            "name": "Doxorubicin",
                            "dose": "50 mg/m²",
                            "route": "IV",
                            "duration": "Over 4 hours"
                        },
                        {
                            "day": "Day 4",
                            "name": "Vincristine",
                            "dose": "2 mg",
                            "route": "IV",
                            "duration": "Push"
                        },
                        {
                            "day": "Day 11-14",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "4 Days"
                        },
                        {
                            "day": "Day 11",
                            "name": "Vincristine",
                            "dose": "2 mg",
                            "route": "IV",
                            "duration": "Push"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor for hemorrhagic cystitis; ensure adequate Mesna coverage.",
                        "Strict fluid intake/output monitoring during Cyclophosphamide.",
                        "BM before Vincristine, check for constipation, neuropathy",
                        "Check cardiac function before Doxorubicin; watch for infusion reactions."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "HyperCVAD Cycle B",
                    "drugs": [
                        {
                            "day": "Day 1",
                            "name": "Methotrexate (High Dose)",
                            "dose": "1 g/m²",
                            "route": "IV",
                            "duration": "Over 24 hours"
                        },
                        {
                            "day": "Day 1-3",
                            "name": "Methylprednisolone",
                            "dose": "50 mg every 12 hours",
                            "route": "IV",
                            "duration": "3 Days"
                        },
                        {
                            "day": "Day 2 (36 hours after start of MTX)",
                            "name": "Leucovorin Rescue",
                            "dose": "15 mg every 6 hours",
                            "route": "IV/PO",
                            "duration": "Until methotrexate level <0.1"
                        },
                        {
                            "day": "Day 2-3",
                            "name": "Cytarabine",
                            "dose": "3 g/m² every 12 hours × 4 doses",
                            "route": "IV",
                            "duration": "Over 3 hours"
                        }
                    ],
                    "NursesInfo": [
                        "Check urine pH daily and maintain pH > 8 during high-dose Methotrexate.",
                        "MTX level daily 24 hours after MTX started",
                        "Monitor for Cytarabine",
                        "Ensure steroid-induced hyperglycemia monitoring.",
                        "Eye-drop prophylaxis required for high-dose Cytarabine (Prednisolone drops)."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Maintenance Therapy": {
            "goal": "To maintain remission and prevent relapse.",
            "protocols": [
                {
                    "protocolName": "POMP Regimen",
                    "drugs": [
                        {
                            "day": "Daily",
                            "name": "6-Mercaptopurine",
                            "dose": "50–75 mg/m²",
                            "route": "Oral",
                            "duration": "2 years"
                        },
                        {
                            "day": "Weekly",
                            "name": "Methotrexate",
                            "dose": "20 mg/m²",
                            "route": "Oral",
                            "duration": "2 years"
                        },
                        {
                            "day": "Monthly",
                            "name": "Vincristine",
                            "dose": "1.4 mg/m²",
                            "route": "IV",
                            "duration": "Monthly"
                        },
                        {
                            "day": "Monthly",
                            "name": "Prednisone",
                            "dose": "40 mg/m²",
                            "route": "Oral",
                            "duration": "5 days each cycle"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor CBC, LFTs, and infection signs; encourage adherence to oral meds."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "CNS Prophylaxis": {
            "goal": "To prevent central nervous system relapse.",
            "protocols": [
                {
                    "protocolName": "Intrathecal Therapy",
                    "drugs": [
                        {
                            "day": "Scheduled",
                            "name": "Methotrexate ± Cytarabine ± Hydrocortisone",
                            "dose": "Per center protocol",
                            "route": "Intrathecal",
                            "duration": "As scheduled"
                        }
                    ],
                    "NursesInfo": [
                        "Ensure proper patient positioning post-procedure; monitor for headache or nausea."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Salvage / Relapse Therapy": {
            "goal": "To achieve remission in relapsed or refractory cases.",
            "protocols": [
                {
                    "protocolName": "Blinatumomab / Inotuzumab / CAR-T",
                    "drugs": [
                        {
                            "name": "Blinatumomab",
                            "dose": "As per MRD status",
                            "route": "IV",
                            "duration": "Continuous 28 days"
                        },
                        {
                            "name": "Inotuzumab ozogamicin",
                            "dose": "0.8 mg/m² → 0.5 mg/m²",
                            "route": "IV",
                            "duration": "Cycle-based"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor for cytokine release and veno-occlusive disease; consider transplant if eligible."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        }
    },
    "CML": {
        "Chronic Phase": {
            "goal": "To suppress BCR-ABL activity, prevent progression, and maintain long-term remission.",
            "protocols": [
                {
                    "protocolName": "Imatinib (First-Line TKI)",
                    "drugs": [
                        {
                            "day": "Daily",
                            "name": "Imatinib",
                            "dose": "400 mg once daily",
                            "route": "Oral",
                            "duration": "Continuous"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor CBC and liver enzymes every 2–4 weeks initially.",
                        "Assess adherence — missed doses can lead to resistance.",
                        "Take with food and a full glass of water to reduce GI upset."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Dasatinib",
                    "drugs": [
                        {
                            "day": "Daily",
                            "name": "Dasatinib",
                            "dose": "100 mg once daily",
                            "route": "Oral",
                            "duration": "Continuous"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor for pleural effusion — report dyspnea or cough.",
                        "Avoid concurrent PPIs (reduces absorption).",
                        "Frequent CBC checks due to potential cytopenias."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Nilotinib",
                    "drugs": [
                        {
                            "day": "Every 12 hours",
                            "name": "Nilotinib",
                            "dose": "300 mg twice daily",
                            "route": "Oral",
                            "duration": "Continuous"
                        }
                    ],
                    "NursesInfo": [
                        "Give on an empty stomach (avoid food 2 hours before and 1 hour after).",
                        "Monitor ECG for QT prolongation.",
                        "Frequent monitoring of glucose and lipids."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Accelerated Phase": {
            "goal": "To regain hematologic control and prevent transition to blast crisis.",
            "protocols": [
                {
                    "protocolName": "High-Dose Imatinib",
                    "drugs": [
                        {
                            "day": "Daily",
                            "name": "Imatinib",
                            "dose": "600–800 mg daily",
                            "route": "Oral",
                            "duration": "Continuous"
                        }
                    ],
                    "NursesInfo": [
                        "Increased GI and edema risk at higher doses.",
                        "Monitor BCR-ABL transcript levels every 3 months."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Second-Generation TKI (Dasatinib/Nilotinib)",
                    "drugs": [
                        {
                            "day": "Daily",
                            "name": "Dasatinib or Nilotinib",
                            "dose": "Per guideline",
                            "route": "Oral",
                            "duration": "Continuous"
                        }
                    ],
                    "NursesInfo": [
                        "Used when resistance or intolerance to Imatinib occurs.",
                        "Monitor for severe myelosuppression."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Blast Crisis": {
            "goal": "To rapidly control blast proliferation and prepare for transplant when possible.",
            "protocols": [
                {
                    "protocolName": "Third-Generation TKI (Ponatinib)",
                    "drugs": [
                        {
                            "day": "Daily",
                            "name": "Ponatinib",
                            "dose": "15–45 mg daily (mutation-dependent)",
                            "route": "Oral",
                            "duration": "Continuous"
                        }
                    ],
                    "NursesInfo": [
                        "Effective against T315I mutation.",
                        "Monitor for hypertension and vascular events.",
                        "Frequent CBC and liver function monitoring required."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "HyperCVAD A",
                    "drugs": [
                        {
                            "day": "Days 1–3",
                            "name": "Cyclophosphamide",
                            "dose": "300 mg/m² every 12 hours",
                            "route": "IV",
                            "duration": "6 doses"
                        },
                        {
                            "day": "Day 1–3",
                            "name": "Mesna",
                            "dose": "Per protocol",
                            "route": "IV",
                            "duration": "Uroprotection"
                        },
                        {
                            "day": "Day 4 & 11",
                            "name": "Vincristine",
                            "dose": "2 mg",
                            "route": "IV",
                            "duration": "Rapid push"
                        },
                        {
                            "day": "Day 4",
                            "name": "Doxorubicin (Adriamycin)",
                            "dose": "50 mg/m²",
                            "route": "IV",
                            "duration": "Administer slowly"
                        },
                        {
                            "day": "Days 1–4 & 11–14",
                            "name": "Dexamethasone",
                            "dose": "40 mg/day",
                            "route": "Oral/IV",
                            "duration": "Steroid backbone"
                        }
                    ],
                    "NursesInfo": [
                        "Hyperhydration and Mesna are mandatory to prevent hemorrhagic cystitis.",
                        "Monitor for neurotoxicity with vincristine.",
                        "Track cardiac function due to anthracycline exposure.",
                        "Monitor glucose during steroid pulses."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "HyperCVAD B",
                    "drugs": [
                        {
                            "day": "Day 1",
                            "name": "Methotrexate",
                            "dose": "1 g/m²",
                            "route": "IV",
                            "duration": "Over several hours"
                        },
                        {
                            "day": "Day 2",
                            "name": "Cytarabine",
                            "dose": "3 g/m² every 12 hours × 2 doses",
                            "route": "IV",
                            "duration": "High-dose"
                        },
                        {
                            "day": "Multiple Days",
                            "name": "Leucovorin Rescue",
                            "dose": "Per protocol",
                            "route": "IV/Oral",
                            "duration": "Begin 24 hours post-MTX"
                        }
                    ],
                    "NursesInfo": [
                        "Strict hydration and urine alkalinization required for MTX safety.",
                        "Monitor for cerebellar toxicity with high-dose Cytarabine.",
                        "Daily lab monitoring: renal function, MTX levels.",
                        "Eye drop prophylaxis for Cytarabine."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        }
    },
    "CLL": {
        "Frontline Therapy": {
            "goal": "To control disease, achieve deep remissions, and minimize treatment toxicity using targeted or chemo-immunotherapy regimens.",
            "protocols": [
                {
                    "protocolName": "Venetoclax + Obinutuzumab (Modern First-Line)",
                    "drugs": [
                        {
                            "day": "Cycle 1 (Day 1, 2, 8, 15)",
                            "name": "Obinutuzumab",
                            "dose": "100 mg → 900 mg → 1000 mg",
                            "route": "IV",
                            "duration": "Per infusion protocol"
                        },
                        {
                            "day": "Cycle 1–6",
                            "name": "Venetoclax",
                            "dose": "20 → 50 → 100 → 200 → 400 mg ramp-up",
                            "route": "PO",
                            "duration": "Daily after ramp-up"
                        }
                    ],
                    "NursesInfo": [
                        "TLS risk highest during Venetoclax ramp-up; ensure hydration and monitoring.",
                        "Premedicate before Obinutuzumab to avoid infusion reactions.",
                        "Monitor lymphocyte count and tumor burden closely."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Acalabrutinib (BTK Inhibitor)",
                    "drugs": [
                        {
                            "day": "Continuous",
                            "name": "Acalabrutinib",
                            "dose": "100 mg twice daily",
                            "route": "PO",
                            "duration": "Continuous"
                        }
                    ],
                    "NursesInfo": [
                        "Lower bleeding risk than ibrutinib but still significant; assess platelet inhibitors.",
                        "Avoid PPIs — reduces Acalabrutinib absorption.",
                        "Monitor for headaches; usually improves with caffeine or simple analgesics."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Zanubrutinib",
                    "drugs": [
                        {
                            "day": "Continuous",
                            "name": "Zanubrutinib",
                            "dose": "160 mg twice daily or 320 mg daily",
                            "route": "PO",
                            "duration": "Continuous"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor BP and heart rhythm; BTK inhibitors increase AF risk.",
                        "Check for bruising or minor bleeding.",
                        "Preferred over ibrutinib due to better tolerability."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Ibrutinib (Older BTKi)",
                    "drugs": [
                        {
                            "day": "Continuous",
                            "name": "Ibrutinib",
                            "dose": "420 mg daily",
                            "route": "PO",
                            "duration": "Continuous"
                        }
                    ],
                    "NursesInfo": [
                        "Higher cardiac toxicity than newer BTKi; monitor for palpitations.",
                        "Watch for bruising, diarrhea, muscle cramps.",
                        "Avoid strong CYP3A inhibitors."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "FCR (Fludarabine + Cyclophosphamide + Rituximab) — Classic",
                    "drugs": [
                        {
                            "day": "Days 1–3",
                            "name": "Fludarabine",
                            "dose": "25 mg/m²",
                            "route": "IV",
                            "duration": "Per protocol"
                        },
                        {
                            "day": "Days 1–3",
                            "name": "Cyclophosphamide",
                            "dose": "250 mg/m²",
                            "route": "IV",
                            "duration": "Per protocol"
                        },
                        {
                            "day": "Day 1",
                            "name": "Rituximab",
                            "dose": "375 mg/m² first cycle → 500 mg/m²",
                            "route": "IV",
                            "duration": "Premedicate required"
                        }
                    ],
                    "NursesInfo": [
                        "High immunosuppression risk — infection prophylaxis necessary.",
                        "Requires antiviral + PJP prophylaxis.",
                        "Monitor for hemolysis in del(17p) or TP53 mutation (FCR not recommended)."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "BR (Bendamustine + Rituximab) — Classic",
                    "drugs": [
                        {
                            "day": "Days 1–2",
                            "name": "Bendamustine",
                            "dose": "90 mg/m²",
                            "route": "IV",
                            "duration": "Per protocol"
                        },
                        {
                            "day": "Day 1",
                            "name": "Rituximab",
                            "dose": "375–500 mg/m²",
                            "route": "IV",
                            "duration": "Premedicate required"
                        }
                    ],
                    "NursesInfo": [
                        "Better tolerated than FCR for older adults.",
                        "Expect cytopenias after cycle 2–3; monitor CBC closely.",
                        "Give antiviral and PJP prophylaxis."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Relapsed/Refractory Therapy": {
            "goal": "To achieve durable remission in patients who relapse after first-line treatment or have high-risk genetic profiles.",
            "protocols": [
                {
                    "protocolName": "Venetoclax + Rituximab (Modern R/R)",
                    "drugs": [
                        {
                            "day": "Cycle 1–6",
                            "name": "Venetoclax",
                            "dose": "20 → 400 mg ramp-up",
                            "route": "PO",
                            "duration": "Daily"
                        },
                        {
                            "day": "Cycle 1–6",
                            "name": "Rituximab",
                            "dose": "375 mg/m² → 500 mg/m²",
                            "route": "IV",
                            "duration": "Per schedule"
                        }
                    ],
                    "NursesInfo": [
                        "Highest TLS risk occurs at treatment initiation.",
                        "Needs tumor lysis prophylaxis and lab checks.",
                        "Monitor neutropenia — common with Venetoclax."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Acalabrutinib (BTKi)",
                    "drugs": [
                        {
                            "day": "Continuous",
                            "name": "Acalabrutinib",
                            "dose": "100 mg BID",
                            "route": "PO",
                            "duration": "Continuous"
                        }
                    ],
                    "NursesInfo": [
                        "Preferred for patients intolerant to ibrutinib.",
                        "Monitor for headaches, AFib, bleeding.",
                        "Avoid PPIs."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Pirtobrutinib (Next-Gen BTKi)",
                    "drugs": [
                        {
                            "day": "Continuous",
                            "name": "Pirtobrutinib",
                            "dose": "200 mg daily",
                            "route": "PO",
                            "duration": "Continuous"
                        }
                    ],
                    "NursesInfo": [
                        "Useful even after failure of other BTK inhibitors.",
                        "Generally well tolerated; monitor for infections.",
                        "Check for bleeding/bruising."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "High-Dose Steroids + Rituximab (Classic R/R)",
                    "drugs": [
                        {
                            "day": "Days 1–3",
                            "name": "Methylprednisolone",
                            "dose": "1 g/day",
                            "route": "IV",
                            "duration": "3 days"
                        },
                        {
                            "day": "Day 1",
                            "name": "Rituximab",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "Premedicate"
                        }
                    ],
                    "NursesInfo": [
                        "Used for refractory CLL or auto-immune cytopenias.",
                        "High hyperglycemia risk — monitor sugars.",
                        "Monitor for infusion reactions."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Supportive Care": {
            "goal": "To manage complications associated with CLL and its treatments.",
            "protocols": [
                {
                    "protocolName": "Infection Prophylaxis",
                    "drugs": [],
                    "NursesInfo": [
                        "Give antiviral prophylaxis during anti-CD20 or FCR/BR therapy.",
                        "Provide PJP prophylaxis with fludarabine-based regimens.",
                        "Vaccinate (influenza, COVID, pneumococcal) — avoid live vaccines."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Hypogammaglobulinemia Management",
                    "drugs": [
                        {
                            "day": "Monthly",
                            "name": "IVIG",
                            "dose": "0.3–0.5 g/kg",
                            "route": "IV",
                            "duration": "Slow infusion"
                        }
                    ],
                    "NursesInfo": [
                        "Indicated for recurrent bacterial infections.",
                        "Monitor for allergic reactions or headache."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Tumor Lysis Syndrome Prevention",
                    "drugs": [
                        {
                            "day": "Per protocol",
                            "name": "Allopurinol",
                            "dose": "100–300 mg/day",
                            "route": "PO",
                            "duration": "Start 2–3 days prior"
                        },
                        {
                            "day": "High-risk cases",
                            "name": "Rasburicase",
                            "dose": "6 mg single dose",
                            "route": "IV",
                            "duration": "One-time"
                        }
                    ],
                    "NursesInfo": [
                        "TLS risk highest with Venetoclax initiation.",
                        "Ensure aggressive hydration and serial labs.",
                        "Monitor potassium, uric acid, phosphate closely."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        }
    },
    "APL": {
        "Induction Therapy": {
            "goal": "To achieve remission by rapidly reducing leukemic promyelocytes using differentiation therapy.",
            "protocols": [
                {
                    "protocolName": "ATRA + ATO (Standard-Risk APL)",
                    "drugs": [
                        {
                            "day": "Day 1–Induction complete",
                            "name": "ATRA (Tretinoin)",
                            "dose": "45 mg/m²/day divided BID",
                            "route": "Oral",
                            "duration": "Daily"
                        },
                        {
                            "day": "Days 1–42",
                            "name": "Arsenic Trioxide (ATO)",
                            "dose": "0.15 mg/kg/day",
                            "route": "IV",
                            "duration": "Daily infusion"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor QTc closely — correct low potassium and magnesium before ATO.",
                        "Watch for differentiation syndrome (fever, dyspnea, weight gain) — start steroids immediately.",
                        "Ensure central line access for repeated ATO infusions."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "ATRA + Anthracycline (High-Risk APL)",
                    "drugs": [
                        {
                            "day": "Day 1–Induction complete",
                            "name": "ATRA (Tretinoin)",
                            "dose": "45 mg/m²/day divided BID",
                            "route": "Oral",
                            "duration": "Daily"
                        },
                        {
                            "day": "Day 1",
                            "name": "Idarubicin",
                            "dose": "12 mg/m²",
                            "route": "IV",
                            "duration": "Single dose or per protocol"
                        },
                        {
                            "day": "Additional",
                            "name": "ATO (optional)",
                            "dose": "0.15 mg/kg/day",
                            "route": "IV",
                            "duration": "Center-specific"
                        }
                    ],
                    "NursesInfo": [
                        "High-risk APL = WBC > 10 × 10⁹/L — requires anthracycline support.",
                        "Monitor for coagulopathy — APL patients have DIC risk.",
                        "Check cardiac function when using anthracyclines."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Consolidation Therapy": {
            "goal": "To deepen remission and eliminate minimal residual disease.",
            "protocols": [
                {
                    "protocolName": "ATRA + ATO Cycles (Standard-Risk)",
                    "drugs": [
                        {
                            "day": "ATRA",
                            "name": "ATRA",
                            "dose": "45 mg/m²/day",
                            "route": "Oral",
                            "duration": "2 weeks on / 2 weeks off"
                        },
                        {
                            "day": "ATO",
                            "name": "Arsenic Trioxide",
                            "dose": "0.15 mg/kg/day",
                            "route": "IV",
                            "duration": "5 days/week × 4 weeks per cycle"
                        }
                    ],
                    "NursesInfo": [
                        "QTc monitoring remains critical during consolidation.",
                        "Hydration reduces ATO toxicity.",
                        "Assess LFTs weekly; hold if severe elevation."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "ATRA + Chemotherapy (High-Risk)",
                    "drugs": [
                        {
                            "day": "Cycle-based",
                            "name": "ATRA",
                            "dose": "45 mg/m²/day",
                            "route": "Oral",
                            "duration": "As per cycle"
                        },
                        {
                            "day": "Cycle-based",
                            "name": "Anthracycline (Idarubicin or Daunorubicin)",
                            "dose": "Per protocol",
                            "route": "IV",
                            "duration": "Per cycle"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor cumulative anthracycline exposure.",
                        "Consider ATO addition based on MRD levels.",
                        "Expected cytopenias — monitor CBC regularly."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Maintenance Therapy": {
            "goal": "To prevent relapse after achieving molecular remission, especially in high-risk patients.",
            "protocols": [
                {
                    "protocolName": "ATRA + 6-MP + Methotrexate",
                    "drugs": [
                        {
                            "day": "Days 1–14 (every 3 months)",
                            "name": "ATRA",
                            "dose": "45 mg/m²/day",
                            "route": "Oral",
                            "duration": "14-day pulse"
                        },
                        {
                            "day": "Daily",
                            "name": "6-Mercaptopurine",
                            "dose": "50–75 mg/m²/day",
                            "route": "Oral",
                            "duration": "Continuous"
                        },
                        {
                            "day": "Weekly",
                            "name": "Methotrexate",
                            "dose": "15 mg/m²",
                            "route": "Oral",
                            "duration": "Weekly"
                        }
                    ],
                    "NursesInfo": [
                        "CBC and LFT monitoring mandatory due to 6-MP and MTX toxicity.",
                        "Educate patient to avoid alcohol with methotrexate.",
                        "Check for mucositis and bone marrow suppression."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Supportive Care": {
            "goal": "To manage complications unique to APL, especially coagulopathy and differentiation syndrome.",
            "protocols": [
                {
                    "protocolName": "Coagulopathy Management",
                    "drugs": [
                        {
                            "day": "As needed",
                            "name": "Cryoprecipitate",
                            "dose": "Maintain fibrinogen > 150 mg/dL",
                            "route": "IV",
                            "duration": "Per transfusion"
                        },
                        {
                            "day": "As needed",
                            "name": "Platelets",
                            "dose": "Maintain > 30–50 ×10⁹/L",
                            "route": "IV",
                            "duration": "Per transfusion"
                        }
                    ],
                    "NursesInfo": [
                        "APL induction frequently presents with DIC.",
                        "Maintain aggressive transfusion support early in treatment.",
                        "Monitor coagulation profile daily during induction."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Differentiation Syndrome Prophylaxis",
                    "drugs": [
                        {
                            "day": "Early sign onset",
                            "name": "Dexamethasone",
                            "dose": "10 mg IV twice daily",
                            "route": "IV",
                            "duration": "Until symptoms resolve"
                        }
                    ],
                    "NursesInfo": [
                        "Symptoms: fever, dyspnea, weight gain, edema.",
                        "Start steroids immediately — do NOT wait for confirmatory tests.",
                        "Hold ATRA/ATO temporarily in severe cases."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        }
    },
    "MM": {
        "Induction Therapy": {
            "goal": "To achieve rapid disease control and prepare eligible patients for stem-cell transplantation.",
            "protocols": [
                {
                    "protocolName": "VRd (Bortezomib + Lenalidomide + Dexamethasone)",
                    "drugs": [
                        {
                            "day": "Days 1, 4, 8, 11",
                            "name": "Bortezomib",
                            "dose": "1.3 mg/m²",
                            "route": "SC or IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Days 1–14",
                            "name": "Lenalidomide",
                            "dose": "25 mg daily",
                            "route": "PO",
                            "duration": "Daily × 14 days"
                        },
                        {
                            "day": "Days 1, 8, 15",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "Weekly"
                        }
                    ],
                    "NursesInfo": [
                        "Use SC route for bortezomib to reduce neuropathy risk.",
                        "Monitor CBC; both bortezomib and lenalidomide cause cytopenia.",
                        "Start antiviral prophylaxis (acyclovir) to prevent VZV reactivation."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Dara-VRd (Daratumumab + VRd)",
                    "drugs": [
                        {
                            "day": "Weekly during cycles 1–2",
                            "name": "Daratumumab",
                            "dose": "16 mg/kg (IV) or 1,800 mg (SC)",
                            "route": "IV/SC",
                            "duration": "As per infusion protocol"
                        },
                        {
                            "day": "Days 1, 4, 8, 11",
                            "name": "Bortezomib",
                            "dose": "1.3 mg/m²",
                            "route": "SC",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Days 1–14",
                            "name": "Lenalidomide",
                            "dose": "25 mg",
                            "route": "PO",
                            "duration": "Daily"
                        },
                        {
                            "day": "Days 1, 8, 15",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "Weekly"
                        }
                    ],
                    "NursesInfo": [
                        "Premedicate Daratumumab: steroid, antihistamine, antipyretic.",
                        "Monitor closely for infusion-related reactions during first dose.",
                        "Ensure antiviral prophylaxis and infection monitoring."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "KRd (Carfilzomib + Lenalidomide + Dexamethasone)",
                    "drugs": [
                        {
                            "day": "Days 1, 2, 8, 9, 15, 16",
                            "name": "Carfilzomib",
                            "dose": "20 mg/m² → 36–56 mg/m²",
                            "route": "IV",
                            "duration": "30 minutes"
                        },
                        {
                            "day": "Days 1–21",
                            "name": "Lenalidomide",
                            "dose": "25 mg daily",
                            "route": "PO",
                            "duration": "Daily × 21 days"
                        },
                        {
                            "day": "Weekly",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "Weekly"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor for hypertension and cardiac events—carfilzomib increases risk.",
                        "Ensure hydration pre- and post-infusion.",
                        "Avoid in uncontrolled cardiac conditions."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Consolidation Therapy": {
            "goal": "To deepen response after induction or following autologous stem-cell transplantation.",
            "protocols": [
                {
                    "protocolName": "Post-Transplant VRd × 2–4 cycles",
                    "drugs": [
                        {
                            "day": "1, 4, 8, 11",
                            "name": "Bortezomib",
                            "dose": "1.3 mg/m²",
                            "route": "SC",
                            "duration": "Bolus"
                        },
                        {
                            "day": "1–14",
                            "name": "Lenalidomide",
                            "dose": "10–15 mg",
                            "route": "PO",
                            "duration": "Daily"
                        },
                        {
                            "day": "1, 8, 15",
                            "name": "Dexamethasone",
                            "dose": "20–40 mg",
                            "route": "PO/IV",
                            "duration": "Weekly"
                        }
                    ],
                    "NursesInfo": [
                        "Often used for high-risk cytogenetics.",
                        "Continue antiviral prophylaxis with bortezomib.",
                        "Monitor neuropathy and blood counts."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "KRd Consolidation",
                    "drugs": [
                        {
                            "day": "1, 2, 8, 9, 15, 16",
                            "name": "Carfilzomib",
                            "dose": "36–56 mg/m²",
                            "route": "IV",
                            "duration": "30 minutes"
                        },
                        {
                            "day": "1–21",
                            "name": "Lenalidomide",
                            "dose": "10–15 mg",
                            "route": "PO",
                            "duration": "Daily"
                        },
                        {
                            "day": "Weekly",
                            "name": "Dexamethasone",
                            "dose": "20–40 mg",
                            "route": "PO/IV",
                            "duration": "Weekly"
                        }
                    ],
                    "NursesInfo": [
                        "Used especially in high-risk cytogenetics (del17p, t(4;14)).",
                        "Monitor BP and cardiac status during carfilzomib."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Maintenance Therapy": {
            "goal": "To prolong progression-free survival and maintain remission after induction or transplant.",
            "protocols": [
                {
                    "protocolName": "Lenalidomide Maintenance",
                    "drugs": [
                        {
                            "day": "Days 1–21 of each 28-day cycle",
                            "name": "Lenalidomide",
                            "dose": "10 mg",
                            "route": "PO",
                            "duration": "Daily × 21 days"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor for cytopenias every cycle.",
                        "Assess thrombosis risk → consider aspirin prophylaxis.",
                        "Watch for fatigue and secondary malignancy risk."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Bortezomib Maintenance (High-Risk)",
                    "drugs": [
                        {
                            "day": "Every 2 weeks",
                            "name": "Bortezomib",
                            "dose": "1.3 mg/m²",
                            "route": "SC",
                            "duration": "Bolus"
                        }
                    ],
                    "NursesInfo": [
                        "Preferred for high-risk cytogenetics (del17p, t(4;14)).",
                        "Monitor for neuropathy and shingles reactivation.",
                        "Continue antiviral prophylaxis."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Relapsed/Refractory Therapy": {
            "goal": "To regain disease control after progression and improve survival.",
            "protocols": [
                {
                    "protocolName": "Daratumumab (Mono or Combo)",
                    "drugs": [
                        {
                            "day": "Weekly × 8 then spaced",
                            "name": "Daratumumab",
                            "dose": "16 mg/kg IV or 1,800 mg SC",
                            "route": "IV/SC",
                            "duration": "As per schedule"
                        }
                    ],
                    "NursesInfo": [
                        "Premedicate with steroid, antihistamine, antipyretic.",
                        "Monitor for infusion reactions—most occur with first dose.",
                        "Ensure blood bank aware: daratumumab interferes with crossmatching."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Carfilzomib + Dexamethasone (Kd)",
                    "drugs": [
                        {
                            "day": "1, 2, 8, 9, 15, 16",
                            "name": "Carfilzomib",
                            "dose": "56–70 mg/m²",
                            "route": "IV",
                            "duration": "30 minutes"
                        },
                        {
                            "day": "Weekly",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "Weekly"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor for cardiac failure, hypertension, and dyspnea.",
                        "Hydrate before infusion but avoid fluid overload."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Pomalidomide + Dexamethasone",
                    "drugs": [
                        {
                            "day": "Days 1–21",
                            "name": "Pomalidomide",
                            "dose": "4 mg",
                            "route": "PO",
                            "duration": "Daily"
                        },
                        {
                            "day": "Weekly",
                            "name": "Dexamethasone",
                            "dose": "20–40 mg",
                            "route": "PO/IV",
                            "duration": "Weekly"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor cytopenias—pomalidomide causes severe neutropenia.",
                        "Thrombosis prophylaxis required.",
                        "Watch for infection and fatigue."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Teclistamab (Bispecific Antibody)",
                    "drugs": [
                        {
                            "day": "Dose escalation then weekly",
                            "name": "Teclistamab",
                            "dose": "Step-up dosing",
                            "route": "SC",
                            "duration": "Weekly"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor for CRS (cytokine release syndrome) — fever, hypotension.",
                        "Monitor for ICANS (neurotoxicity).",
                        "Hospital admission recommended during initial step-up dosing."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        }
    },
    "HL": {
        "First-Line Therapy": {
            "goal": "To achieve complete remission using combination chemotherapy with or without radiotherapy.",
            "protocols": [
                {
                    "protocolName": "ABVD (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)",
                    "drugs": [
                        {
                            "day": "Day 1 & 15 (28-day cycle)",
                            "name": "Doxorubicin (Adriamycin)",
                            "dose": "25 mg/m²",
                            "route": "IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Day 1 & 15",
                            "name": "Bleomycin",
                            "dose": "10 units/m²",
                            "route": "IV",
                            "duration": "Slow push / short infusion"
                        },
                        {
                            "day": "Day 1 & 15",
                            "name": "Vinblastine",
                            "dose": "6 mg/m²",
                            "route": "IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Day 1 & 15",
                            "name": "Dacarbazine",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "30–60 min"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor pulmonary function – bleomycin is associated with lung toxicity.",
                        "Avoid giving supplemental oxygen unless necessary.",
                        "Anthracycline (doxorubicin) may cause cardiotoxicity – check baseline EF.",
                        "Use central access due to vesicant risk (vinblastine, doxorubicin)."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Brentuximab + AVD (ECHELON-1 regimen)",
                    "drugs": [
                        {
                            "day": "Day 1 & 15",
                            "name": "Brentuximab Vedotin",
                            "dose": "1.2 mg/kg",
                            "route": "IV",
                            "duration": "30 min"
                        },
                        {
                            "day": "Day 1 & 15",
                            "name": "Doxorubicin",
                            "dose": "25 mg/m²",
                            "route": "IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Day 1 & 15",
                            "name": "Vinblastine",
                            "dose": "6 mg/m²",
                            "route": "IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Day 1 & 15",
                            "name": "Dacarbazine",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "30–60 min"
                        }
                    ],
                    "NursesInfo": [
                        "Brentuximab may cause peripheral neuropathy – monitor closely.",
                        "Avoid bleomycin when giving Brentuximab.",
                        "Premedicate as per protocol to reduce infusion reactions.",
                        "Monitor liver enzymes and CBC every cycle."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Second-Line / Salvage Therapy": {
            "goal": "To achieve remission in relapsed or refractory disease and prepare for autologous stem-cell transplant (ASCT).",
            "protocols": [
                {
                    "protocolName": "ICE (Ifosfamide + Carboplatin + Etoposide)",
                    "drugs": [
                        {
                            "day": "Days 1–3",
                            "name": "Ifosfamide + Mesna",
                            "dose": "5 g/m² total",
                            "route": "IV",
                            "duration": "Continuous or fractionated"
                        },
                        {
                            "day": "Day 2",
                            "name": "Carboplatin",
                            "dose": "AUC 5",
                            "route": "IV",
                            "duration": "60 min"
                        },
                        {
                            "day": "Days 1–3",
                            "name": "Etoposide",
                            "dose": "100 mg/m²/day",
                            "route": "IV",
                            "duration": "60 min"
                        }
                    ],
                    "NursesInfo": [
                        "Mesna must be given with ifosfamide to prevent hemorrhagic cystitis.",
                        "Ensure daily urinalysis for hematuria on ifosfamide.",
                        "Monitor nephrotoxicity and electrolytes (carboplatin).",
                        "High risk of neutropenia – G-CSF support recommended."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "GDP (Gemcitabine + Dexamethasone + Cisplatin)",
                    "drugs": [
                        {
                            "day": "Days 1 & 8",
                            "name": "Gemcitabine",
                            "dose": "1000 mg/m²",
                            "route": "IV",
                            "duration": "30 min"
                        },
                        {
                            "day": "Days 1–4",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "Daily × 4 days"
                        },
                        {
                            "day": "Day 1",
                            "name": "Cisplatin",
                            "dose": "75 mg/m²",
                            "route": "IV",
                            "duration": "Continuous or split dosing"
                        }
                    ],
                    "NursesInfo": [
                        "Hydrate before and after cisplatin to reduce kidney injury.",
                        "Monitor for ototoxicity and neuropathy.",
                        "Gemcitabine may cause thrombocytopenia—check CBC before each dose.",
                        "Encourage good oral hydration throughout treatment."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Maintenance / Post-Transplant": {
            "goal": "To prolong remission after autologous stem-cell transplantation.",
            "protocols": [
                {
                    "protocolName": "Brentuximab Maintenance",
                    "drugs": [
                        {
                            "day": "Every 3 weeks",
                            "name": "Brentuximab Vedotin",
                            "dose": "1.8 mg/kg",
                            "route": "IV",
                            "duration": "30 minutes"
                        }
                    ],
                    "NursesInfo": [
                        "Preferred in high-risk relapsed HL post-ASCT.",
                        "Monitor neuropathy and liver function each cycle.",
                        "Premedicate if prior infusion reactions occurred."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        }
    },
    "NHL": {
        "First-Line Therapy": {
            "goal": "To achieve remission using subtype-specific chemotherapy and targeted agents.",
            "protocols": [
                {
                    "protocolName": "R-CHOP (DLBCL Standard)",
                    "drugs": [
                        {
                            "day": "Day 1",
                            "name": "Rituximab",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "Varies (slow initial titration)"
                        },
                        {
                            "day": "Day 1",
                            "name": "Cyclophosphamide",
                            "dose": "750 mg/m²",
                            "route": "IV",
                            "duration": "30–60 min"
                        },
                        {
                            "day": "Day 1",
                            "name": "Doxorubicin",
                            "dose": "50 mg/m²",
                            "route": "IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Day 1",
                            "name": "Vincristine",
                            "dose": "1.4 mg/m² (max 2 mg)",
                            "route": "IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Days 1–5",
                            "name": "Prednisone",
                            "dose": "100 mg/day",
                            "route": "PO",
                            "duration": "5 days"
                        }
                    ],
                    "NursesInfo": [
                        "Pre-medicate before Rituximab (acetaminophen + antihistamine).",
                        "Monitor closely during first Rituximab infusion for infusion reactions.",
                        "Vincristine is a vesicant—avoid extravasation and NEVER give intrathecally.",
                        "Check cardiac function before doxorubicin (anthracycline)."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "R-EPOCH (DLBCL, high-risk or double-hit)",
                    "drugs": [
                        {
                            "day": "Day 1",
                            "name": "Rituximab",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "Slow titrated infusion"
                        },
                        {
                            "day": "Days 1–4",
                            "name": "Etoposide",
                            "dose": "50 mg/m²/day",
                            "route": "IV",
                            "duration": "Continuous infusion"
                        },
                        {
                            "day": "Days 1–4",
                            "name": "Doxorubicin",
                            "dose": "10 mg/m²/day",
                            "route": "IV",
                            "duration": "Continuous infusion"
                        },
                        {
                            "day": "Days 1–4",
                            "name": "Vincristine",
                            "dose": "0.4 mg/m²/day",
                            "route": "IV",
                            "duration": "Continuous infusion"
                        },
                        {
                            "day": "Day 5",
                            "name": "Cyclophosphamide",
                            "dose": "750 mg/m²",
                            "route": "IV",
                            "duration": "60 min"
                        },
                        {
                            "day": "Days 1–5",
                            "name": "Prednisone",
                            "dose": "60 mg/m²/day",
                            "route": "PO",
                            "duration": "5 days"
                        }
                    ],
                    "NursesInfo": [
                        "Requires central line—multiple continuous infusions.",
                        "Vincristine/doxorubicin/etoposide in same CVC lumen for continuous infusion.",
                        "Monitor tumor lysis risk in high-grade lymphomas.",
                        "Daily CBC monitoring due to high risk of cytopenias."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Bendamustine + Rituximab (BR) — Follicular / Indolent NHL",
                    "drugs": [
                        {
                            "day": "Day 1",
                            "name": "Rituximab",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "Slow initial infusion"
                        },
                        {
                            "day": "Days 1–2",
                            "name": "Bendamustine",
                            "dose": "90 mg/m²/day",
                            "route": "IV",
                            "duration": "30–60 min"
                        }
                    ],
                    "NursesInfo": [
                        "Give antiviral prophylaxis (risk of HBV and viral reactivation).",
                        "Infusion reactions possible with Rituximab—observe closely.",
                        "High risk of lymphopenia—monitor for infections.",
                        "Ensure good hydration to prevent nausea and headaches."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Second-Line / Relapsed Therapy": {
            "goal": "To achieve disease control or remission and prepare eligible patients for transplant.",
            "protocols": [
                {
                    "protocolName": "DHAP (Dexamethasone + High-Dose Cytarabine + Cisplatin)",
                    "drugs": [
                        {
                            "day": "Days 1–4",
                            "name": "Dexamethasone",
                            "dose": "40 mg/day",
                            "route": "IV/PO",
                            "duration": "4 days"
                        },
                        {
                            "day": "Day 1",
                            "name": "Cisplatin",
                            "dose": "100 mg/m²",
                            "route": "IV",
                            "duration": "24-hour continuous infusion"
                        },
                        {
                            "day": "Day 2",
                            "name": "Cytarabine",
                            "dose": "2 g/m² × 2 doses",
                            "route": "IV",
                            "duration": "3-hour infusion each"
                        }
                    ],
                    "NursesInfo": [
                        "Hydrate aggressively with cisplatin—monitor renal function.",
                        "Check neuro signs before each high-dose cytarabine dose.",
                        "High nausea risk—use triple antiemetic prophylaxis.",
                        "Monitor electrolytes during cisplatin infusion."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "R-GDP (Rituximab + Gemcitabine + Dexamethasone + Cisplatin)",
                    "drugs": [
                        {
                            "day": "Day 1",
                            "name": "Rituximab",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "Slow titrated infusion"
                        },
                        {
                            "day": "Days 1 & 8",
                            "name": "Gemcitabine",
                            "dose": "1000 mg/m²",
                            "route": "IV",
                            "duration": "30 min"
                        },
                        {
                            "day": "Days 1–4",
                            "name": "Dexamethasone",
                            "dose": "40 mg/day",
                            "route": "PO/IV",
                            "duration": "4 days"
                        },
                        {
                            "day": "Day 1 or 2",
                            "name": "Cisplatin",
                            "dose": "75 mg/m²",
                            "route": "IV",
                            "duration": "Varies"
                        }
                    ],
                    "NursesInfo": [
                        "Check CBC before each gemcitabine dose—risk of thrombocytopenia.",
                        "Monitor for cisplatin nephrotoxicity.",
                        "Premedicate before Rituximab.",
                        "Use adequate hydration to prevent nausea and renal injury."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Maintenance Therapy": {
            "goal": "To prolong remission, especially in follicular and indolent lymphomas.",
            "protocols": [
                {
                    "protocolName": "Rituximab Maintenance",
                    "drugs": [
                        {
                            "day": "Every 2–3 months",
                            "name": "Rituximab",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "Titrated infusion"
                        }
                    ],
                    "NursesInfo": [
                        "Used after BR or R-CHOP in follicular lymphoma.",
                        "Monitor for infusion reactions throughout therapy.",
                        "Assess immunoglobulin levels periodically (risk of hypogammaglobulinemia).",
                        "Screen for HBV before initiation and during therapy."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        }
    },
    "MDS": {
        "Supportive & Symptom-Directed Therapy": {
            "goal": "To improve quality of life, correct cytopenias, and reduce transfusion dependency.",
            "protocols": [
                {
                    "protocolName": "Erythropoietin-Stimulating Agents (ESA)",
                    "drugs": [
                        {
                            "day": "Weekly / Q2 weeks",
                            "name": "Erythropoietin (EPO)",
                            "dose": "40,000–60,000 units",
                            "route": "SC",
                            "duration": "Once weekly or every 2 weeks"
                        },
                        {
                            "day": "Weekly",
                            "name": "Darbepoetin",
                            "dose": "150–300 mcg",
                            "route": "SC",
                            "duration": "Weekly"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor CBC every 2–4 weeks to assess response.",
                        "Used mainly for lower-risk MDS with anemia.",
                        "Avoid ESA if Hgb > 12 g/dL due to thrombotic risk.",
                        "Check iron studies and replace iron if low."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Luspatercept (for ring sideroblast MDS)",
                    "drugs": [
                        {
                            "day": "Every 3 weeks",
                            "name": "Luspatercept",
                            "dose": "1 mg/kg (titrate to 1.75 mg/kg)",
                            "route": "SC",
                            "duration": "Q3 weeks"
                        }
                    ],
                    "NursesInfo": [
                        "Used in lower-risk MDS with ring sideroblasts or SF3B1 mutation.",
                        "Monitor for hypertension and injection-site reactions.",
                        "Assess transfusion needs to evaluate response."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Disease-Modifying Therapy (Intermediate / High-Risk)": {
            "goal": "To reduce blast progression, delay evolution to AML, and improve survival.",
            "protocols": [
                {
                    "protocolName": "Azacitidine (AZA)",
                    "drugs": [
                        {
                            "day": "Days 1–7",
                            "name": "Azacitidine",
                            "dose": "75 mg/m²/day",
                            "route": "SC or IV",
                            "duration": "Once daily"
                        }
                    ],
                    "NursesInfo": [
                        "This is the most standard first-line therapy for high-risk MDS.",
                        "Responses may take 4–6 cycles—continue unless clear progression.",
                        "Monitor for cytopenias; dose delays are common.",
                        "Premedicate for nausea; SC injections may cause local irritation."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "Decitabine",
                    "drugs": [
                        {
                            "day": "Days 1–5",
                            "name": "Decitabine",
                            "dose": "20 mg/m²/day",
                            "route": "IV",
                            "duration": "1 hour infusion"
                        }
                    ],
                    "NursesInfo": [
                        "Equivalent alternative to azacitidine for higher-risk MDS.",
                        "Higher risk of neutropenia—monitor CBC closely.",
                        "Antimicrobial prophylaxis is often recommended."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "High-Risk / TP53-Mutated Disease": {
            "goal": "To control aggressive disease, bridge to transplant, or offer low-intensity treatment for non-transplant candidates.",
            "protocols": [
                {
                    "protocolName": "Azacitidine + Venetoclax",
                    "drugs": [
                        {
                            "day": "Days 1–7",
                            "name": "Azacitidine",
                            "dose": "75 mg/m²/day",
                            "route": "SC or IV",
                            "duration": "Daily"
                        },
                        {
                            "day": "Days 1–14 or 1–21",
                            "name": "Venetoclax",
                            "dose": "100–400 mg/day (ramp-up)",
                            "route": "PO",
                            "duration": "Daily with ramp-up"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor for tumor lysis syndrome—especially first cycle.",
                        "Significant neutropenia risk—expect antimicrobial prophylaxis.",
                        "Used for very high-risk, TP53-mutated, or AML-evolving MDS."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "CPX-351 (for AML-transformed MDS)",
                    "drugs": [
                        {
                            "day": "Days 1, 3, 5",
                            "name": "CPX-351 (Vyxeos)",
                            "dose": "44 mg/m² daunorubicin + 100 mg/m² cytarabine",
                            "route": "IV",
                            "duration": "90 min infusion"
                        }
                    ],
                    "NursesInfo": [
                        "Used when MDS evolves to AML or in therapy-related MDS.",
                        "Expect prolonged cytopenias—supportive care essential.",
                        "Central line required; premedicate to prevent infusion reactions."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        }
    }
}